1. Home
  2. PTCT vs GRFS Comparison

PTCT vs GRFS Comparison

Compare PTCT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$76.81

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.49

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTCT
GRFS
Founded
1998
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
6.2B
IPO Year
2013
2006

Fundamental Metrics

Financial Performance
Metric
PTCT
GRFS
Price
$76.81
$9.49
Analyst Decision
Buy
Hold
Analyst Count
17
2
Target Price
$73.76
$10.15
AVG Volume (30 Days)
1.2M
452.1K
Earning Date
02-26-2026
07-28-2022
Dividend Yield
N/A
1.50%
EPS Growth
N/A
N/A
EPS
8.94
0.64
Revenue
$1,779,150,000.00
$8,821,017,248.00
Revenue This Year
$127.32
$5.36
Revenue Next Year
N/A
$5.15
P/E Ratio
$8.64
$18.71
Revenue Growth
97.54
7.31
52 Week Low
$35.95
$6.19
52 Week High
$87.50
$11.14

Technical Indicators

Market Signals
Indicator
PTCT
GRFS
Relative Strength Index (RSI) 52.19 63.67
Support Level $74.22 $9.17
Resistance Level $79.10 $9.46
Average True Range (ATR) 2.12 0.19
MACD -0.16 0.04
Stochastic Oscillator 50.16 88.64

Price Performance

Historical Comparison
PTCT
GRFS

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: